J&J to discontinue E.coli vaccine candidate study
Portfolio Pulse from
Johnson & Johnson has announced the discontinuation of a late-stage study for an experimental E.coli vaccine, which was being developed in partnership with Sanofi.
February 13, 2025 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Johnson & Johnson has decided to stop the late-stage study of its E.coli vaccine candidate, which could impact its vaccine development pipeline and partnership with Sanofi.
The discontinuation of the E.coli vaccine study suggests potential setbacks in J&J's vaccine development efforts and could affect investor sentiment negatively in the short term. The partnership with Sanofi may also be impacted.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80